TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17321581

Group type: EXPERIMENTAL
Intervention: Grass pollen mix (sublingual immunotherapy) for 2 years
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Grass pollen mix (sublingual immunotherapy)
Number of subjects: 204
Study: 15224087

Group type: EXPERIMENTAL
Intervention: Improvement in hand function
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Improvement in bladder and bowel function
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Other SCI-related impairments
Number of subjects: 565
Study: 11435009

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 40
Study: 8333263

Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry with brief revision training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Goldmann applanation tonometry without revision training
Number of subjects: 16
Study: 3013568

Group type: EXPERIMENTAL
Intervention: Sulbactam 1g plus ampicillin 2g every 8 hours
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cefoxitin 2g every 8 hours
Number of subjects: 75
Study: 28924870

Group type: EXPERIMENTAL
Intervention: MR309
Number of subjects: 124
Study: 26947668

Group type: EXPERIMENTAL
Intervention: Watermelon extract (6 g daily for 6 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25563795

Group type: EXPERIMENTAL
Intervention: Structured hypocaloric diet
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Exclusion of high-fat dairy (all women)
Number of subjects: 118
Study: 23430142

Group type: EXPERIMENTAL
Intervention: 1% (w/w) AHYP cream applied twice daily for 4 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control cream applied twice daily for 4 weeks
Number of subjects: 15
Study: 21138533

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA (2 g/day) and antioxidant vitamins C (1 g/day) and E (400 IU/day)
Number of subjects: 95
Study: 18426991

Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ
Number of subjects: 131

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 131
Study: 16160711

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12525463

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (600 micro g every 3 h for a maximum of three doses)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vaginal misoprostol (600 micro g every 3 h for a maximum of three doses)
Number of subjects: 80
Study: 10865219

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (25 mg twice daily) plus calcium (1000 mg/day)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Intermittent etidronate (400 mg/day for 14 days) followed by calcium (1000 mg/day for 76 days)
Number of subjects: 118
Study: 9095567

Group type: EXPERIMENTAL
Intervention: Recumbent position
Number of subjects: 100

Group type: COMPARATOR
Intervention: Erect position
Number of subjects: 100
Study: 1363082

Group type: EXPERIMENTAL
Intervention: 0.5% befunolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3321872

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 204

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 204
Study: 30373342

Group type: EXPERIMENTAL
Intervention: Ultrasound guided popliteal sciatic nerve combined saphenous nerve block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 60
Study: 26986055

Group type: EXPERIMENTAL
Intervention: 7% body weight in seated position
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 90/90 position
Number of subjects: 15
Study: 25617159

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (min 0.2 µg/kg/h‐max 1.0 µg/kg/h)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Propofol (min 1.0 mg/kg/h‐max 3.0 mg/kg/h)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 64
Study: 23724525

Group type: EXPERIMENTAL
Intervention: Levonorgestrel‐releasing intrauterine device (LNG‐IUD) for three months
Number of subjects: 104

Group type: COMPARATOR
Intervention: Oral medroxyprogesterone acetate (MPA) for three months
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Levonorgestrel‐releasing intrauterine device (LNG‐IUD) for six months
Number of subjects: 104

Group type: COMPARATOR
Intervention: Oral medroxyprogesterone acetate (MPA) for six months
Number of subjects: 104
Study: 20816027

Group type: EXPERIMENTAL
Intervention: Topiramate (mean endpoint dose = 177.8 ± 134.2 mg/d; range, 50-400 mg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 36
Study: 19832967

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 811
Study: 17084114

Group type: EXPERIMENTAL
Intervention: 2-day immobilization with a soft cervical collar
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 10-day immobilization with a soft cervical collar
Number of subjects: 70
Study: 15641760

Group type: EXPERIMENTAL
Intervention: Fluoridated milk (5 ppm; total amount 1.25 mg F)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-fluoridated control milk
Number of subjects: 15
Study: 11393606

Group type: EXPERIMENTAL
Intervention: Multicomponent smoking treatment (MST)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: MST plus generalization training of smoking cessation to drug and alcohol cessation (MST+G)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: MST
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: MST+G
Number of subjects: 150

Group type: COMPARATOR
Intervention: UC
Number of subjects: 150
Study: 9252088

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (500 mg/day) plus methotrexate (10 mg/week)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid plus placebo
Number of subjects: 25
Study: 8303108

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 3795978

Group type: EXPERIMENTAL
Intervention: Yohimbine (18 mg yohimbine/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31694861

Group type: EXPERIMENTAL
Intervention: RVT-1502 5 mg
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: RVT-1502 10 mg
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: RVT-1502 15 mg
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 29394207

Group type: EXPERIMENTAL
Intervention: Epidural injections of local anesthetic with corticosteroid (n = 200)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Local anesthetic only (lidocaine) (n = 200)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Betamethasone or dexamethasone
Number of subjects: 400
Study: 27107532

Group type: EXPERIMENTAL
Intervention: Bodyweight-supported treadmill training (BWSTT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Treadmill training without bodyweight support
Number of subjects: 45

Group type: COMPARATOR
Intervention: Overground gait training
Number of subjects: 45
Study: 24576881

Group type: EXPERIMENTAL
Intervention: Anisometropia measurement
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Rate of change in anisometropia
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Aniso-axial length (AL) measurement
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Correlation between changes in anisometropia and aniso-AL
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Correlation between changes in anisometropia and myopia progression
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Baseline anisometropia and myopia progression correlation
Number of subjects: 358
Study: 23872228

Group type: EXPERIMENTAL
Intervention: Reassuring health-related feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Threatening health-related feedback
Number of subjects: 0
Study: 20713915

Group type: EXPERIMENTAL
Intervention: Saturated fatty acids
Number of subjects: 28100

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids
Number of subjects: 28100

Group type: EXPERIMENTAL
Intervention: Trans fatty acids
Number of subjects: 28100

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (including ω3 and ω6)
Number of subjects: 28100
Study: 18332704

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive-pressure ventilation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surfactant administration without endotracheal intubation
Number of subjects: 0
Study: 16308014

Group type: EXPERIMENTAL
Intervention: Carpentier‐Edwards PERIMOUNT Magna
Number of subjects: 63

Group type: COMPARATOR
Intervention: Carpentier‐Edwards PERIMOUNT
Number of subjects: 63

Group type: COMPARATOR
Intervention: Edwards Prima Plus
Number of subjects: 63
Study: 12610843

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Interferential current
Number of subjects: 48

Group type: COMPARATOR
Intervention: No stimulation (control)
Number of subjects: 48
Study: 10318654

Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin (CA group)
Number of subjects: 1689

Group type: COMPARATOR
Intervention: Ticlopidine and aspirin (TA group)
Number of subjects: 1689
Study: 8905888

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard chest physical therapy and postural drainage (CPT/PD)
Number of subjects: 29
Study: 1899393

Group type: EXPERIMENTAL
Intervention: hCG-induced ovulation with IUI
Number of subjects: 48

Group type: COMPARATOR
Intervention: hCG-induced ovulation with natural intercourse
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: spontaneous LH surge with IUI
Number of subjects: 48

Group type: COMPARATOR
Intervention: spontaneous ovulation with timed intercourse
Number of subjects: 48
Study: 6133166

Group type: EXPERIMENTAL
Intervention: Received formula sample packet
Number of subjects: 448

Group type: COMPARATOR
Intervention: Control group (did not receive formula sample packet)
Number of subjects: 448
Study: 31328311

Group type: EXPERIMENTAL
Intervention: Pressure-guided CB-PVI
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional CB-PVI
Number of subjects: 60
Study: 28270280

Group type: EXPERIMENTAL
Intervention: CTPA on high-pitch scanning mode at 70 kV tube voltage with 15 ml contrast medium (Group B)
Number of subjects: 70

Group type: COMPARATOR
Intervention: CTPA on conventional scanning mode (120 kV, 80 ml contrast medium) (Group A)
Number of subjects: 70
Study: 26899038

Group type: EXPERIMENTAL
Intervention: Sulfurous water (SW) group (N=47)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Non-sulfurous water (NSW) group (N=50)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (N=43)
Number of subjects: 140
Study: 24805262

Group type: EXPERIMENTAL
Intervention: DHA (30 mg/kg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22492529

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 0
Study: 19463518

Group type: COMPARATOR
Intervention: Vigorous exercise frequency (0, 1, 1 to 2, 3 to 4, 5 to 7 days/week)
Number of subjects: 16921

Group type: COMPARATOR
Intervention: Vigorous exercise frequency in men <50 years of age (0, 1, 1 to 2, 3 to 4, 5 to 7 days/week)
Number of subjects: 16921

Group type: COMPARATOR
Intervention: Vigorous exercise frequency in joggers (0, 1, 1 to 2, 3 to 4, 5 to 7 days/week)
Number of subjects: 16921
Study: 17075807

Group type: EXPERIMENTAL
Intervention: Prednisone (30 mg/day for 2 weeks, 20 mg/day for 1 week, and 10 mg/day for 1 week)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 154
Study: 14717742

Group type: EXPERIMENTAL
Intervention: DX (derivative crossing)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PX (point of crossing)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PQ (point of VCO(2) equivalent rise)
Number of subjects: 19
Study: 12508631

Group type: EXPERIMENTAL
Intervention: Topical phenytoin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study: 9447367

Group type: EXPERIMENTAL
Intervention: Domiciliary care
Number of subjects: 150

Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 150
Study: 7931253

Group type: EXPERIMENTAL
Intervention: MDL 72974A 1 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MDL 72974A 12 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MDL 72974A 24 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3277680

Group type: EXPERIMENTAL
Intervention: Busulfan
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 326

Group type: COMPARATOR
Intervention: Interferon-alpha
Number of subjects: 326
Study: 31357229

Group type: EXPERIMENTAL
Intervention: Resistance training group (RTG)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 28438450

Group type: EXPERIMENTAL
Intervention: Subcuticular MONOCRYL and DERMABOND (SMD)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Staples
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Subcuticular MONOCRYL and DERMABOND (SMD) and Staples
Number of subjects: 129
Study: 26173928

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 6091)
Number of subjects: 9415

Group type: COMPARATOR
Intervention: Control group (n = 3324)
Number of subjects: 9415
Study: 23274077

Group type: EXPERIMENTAL
Intervention: Simulator Group (SG)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional Group (CG)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both Groups
Number of subjects: 27
Study: 21571733

Group type: EXPERIMENTAL
Intervention: Assistive technology (AT) including assistive devices and splints
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Assistive technology (AT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (information only)
Number of subjects: 70
Study: 18364321

Group type: EXPERIMENTAL
Intervention: Taiwanese traditional herbal diet (TTHD) consisting of analgesic herbs (paeony root: licorice root=1:1) and Taiwanese tonic vegetable soup (Lilii bulbus, Nelumbo seed, and Jujube fruit)
Number of subjects: 2466

Group type: COMPARATOR
Intervention: Regular hospital diet (reference group)
Number of subjects: 2466

Group type: COMPARATOR
Intervention: Taiwanese tonic vegetable soup without analgesic herbs (control group)
Number of subjects: 2466
Study: 15014006

Group type: EXPERIMENTAL
Intervention: Autologous formalin‐fixed tumor vaccine (AFTV)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No adjuvant control
Number of subjects: 41
Study: 12409970

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (75 mg daily)
Number of subjects: 18790

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (75 mg daily) in patients with serum creatinine > 1.3 mg/dl
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (75 mg daily) in subgroups at higher global baseline risk or higher initial blood pressures
Number of subjects: 18790
Study: 9613307

Group type: EXPERIMENTAL
Intervention: 5 g EMLA (group E)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 10 ml 1% mepivacaine (group M)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 10 ml 0.25% bupivacaine (group B)
Number of subjects: 54
Study: 7584486

Group type: EXPERIMENTAL
Intervention: XZ‐CD5 0.1 mg kg‐1 day‐1 intravenously with high‐dose methyl‐prednisolone for 10, 14 or 17 doses
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: XZ‐CD5 and cyclosporine (CSA) for 17 doses
Number of subjects: 11
Study: 2782570

Group type: EXPERIMENTAL
Intervention: Anaesthesia in anaesthetic room
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anaesthesia in operating theatre
Number of subjects: 100
Study: 4473

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31437302

Group type: EXPERIMENTAL
Intervention: DNL104 (a centrally penetrant RIPK1 inhibitor)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 31254640

Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg/day titrated to 40 mg/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 70
Study: 28585834

Group type: EXPERIMENTAL
Intervention: Flavan-3-ol-enriched dark chocolate
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Standard dark chocolate
Number of subjects: 42

Group type: COMPARATOR
Intervention: White chocolate
Number of subjects: 42
Study: 26576593

Group type: EXPERIMENTAL
Intervention: Imatinib plus bevacizumab, 7.5 mg/kg i.v. every 3 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Imatinib 400 mg (standard) or 800 mg (for patients with exon 9 KIT mutations)
Number of subjects: 12
Study: 23662289

Group type: EXPERIMENTAL
Intervention: CR oxycodone/CR naloxone (10 mg/5 mg every 12 h, titrated to 20 mg/10 mg, 30 mg/15 mg, or 40 mg/20 mg)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: CR oxycodone/CR naloxone
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 22238849

Group type: EXPERIMENTAL
Intervention: Video feedback and nonnegative social feedback from a confederate
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (watched video of another person's speech)
Number of subjects: 25
Study: 19635893

Group type: EXPERIMENTAL
Intervention: 1 year of WHO MDT (dapsone, clofazimine, rifampin)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: 2 years of WHO MDT
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: 1 month of daily rifampin and daily ofloxacin
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: 1 year of WHO MDT plus an initial 1 month of daily rifampin and daily ofloxacin
Number of subjects: 189
Study: 16413239

Group type: EXPERIMENTAL
Intervention: 500% recombinant human antithrombin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200% recombinant human antithrombin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15570116

Group type: EXPERIMENTAL
Intervention: L3‐L4 disc herniation (study group)
Number of subjects: 37

Group type: COMPARATOR
Intervention: L4‐L5 and L5‐S1 herniation (control group)
Number of subjects: 37
Study: 11157686

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 1480

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1480
Study: 9364542

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2) as a single agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel (20% to 21%) after failing cisplatin-based chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2) and Cisplatin (75 mg/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel (90 mg/m2 without G-CSF support) and Carboplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2 with G-CSF support) and Carboplatin
Number of subjects: 0
Study: 8496758

Group type: COMPARATOR
Intervention: Standard mixture containing 1.25 mmol calcium and 1.5 mmol phosphorus per deciliter (group STAND: n = 12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1.7 mmol calcium and 2.0 mmol phosphorus per deciliter (group HIGH: n = 12)
Number of subjects: 24
Study: 3629488

Group type: EXPERIMENTAL
Intervention: Iron preparations combined with vitamins B12 and B6, copper sulfate, and the combination of iron with the vitamin B group and copper sulfate.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Iron preparations administered for injection.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Subsequent therapy after hemoglobin normalization.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Iron preparations combined with other preparations.
Number of subjects: 250
Study: 30285151

Group type: EXPERIMENTAL
Intervention: Positively Smoke Free‐Mobile (PSF‐M)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study: 28693841

Group type: EXPERIMENTAL
Intervention: Tattooing (T group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No tattooing (C group)
Number of subjects: 80
Study: 27213646

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Menopause Education Control (MEC)
Number of subjects: 106
Study: 23844613

Group type: EXPERIMENTAL
Intervention: Sodium selenite 200 mcg daily for 6 months
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 20964568

Group type: EXPERIMENTAL
Intervention: Topical nitric oxide 3% plus cryotherapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Cryotherapy plus placebo
Number of subjects: 63
Study: 21186534

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV, 10 mg/d)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Other nucleoside analogues (for 19 patients who switched)
Number of subjects: 80
Study: 19007655

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 0
Study: 16798759

Group type: EXPERIMENTAL
Intervention: DDD pacing for 1 month
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Overdrive pacing for 3 months
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: DDD pacing for 4 months
Number of subjects: 92
Study: 11982739

Group type: EXPERIMENTAL
Intervention: High-dose IFN-alpha induction therapy (6 MIU daily for 4 weeks and 3 MIU 3/7 days for 22 weeks)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Conventional IFN-alpha therapy (3 MIU 3/7 days for 26 weeks)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Patients with thyroid dysfunction
Number of subjects: 254

Group type: COMPARATOR
Intervention: Patients without thyroid dysfunction
Number of subjects: 254